KalVista Pharmaceuticals Grants Inducement Stock Options
On October 1, 2025, KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) disclosed that its compensation committee has approved the issuance of stock options as an inducement to two recently hired employees. The total number of shares involved in this grant amounts to 30,000, reflecting the company’s commitment to attracting talent in the competitive pharmaceutical industry. This move is compliant with the requirements set forth in Nasdaq Listing Rule 5635(c)(4), which governs the issuance of stock options to new hires.
The newly issued stock options will have an exercise price corresponding to the closing price of KalVista common stock on the first trading day following the grant date. This structure not only aligns the interests of employees with those of the shareholders but also incentivizes new hires to contribute to the company’s growth and success. The vesting schedule is structured to encourage long-term engagement; one-fourth of the options will vest on the one-year anniversary of the vesting commencement date, with the remaining options vesting in equal monthly installments over the subsequent three years. This ensures that the new employees will need to maintain their service with the company to fully benefit from the stock options granted.
Moreover, each stock option has a validity period of ten years and is subject to the conditions outlined in KalVista’s Inducement Equity Incentive Plan along with a specific stock option agreement that governs the grant. This structured approach to compensation serves as part of the broader strategy of KalVista Pharmaceuticals to enhance its workforce while also adhering to regulatory standards.
About KalVista Pharmaceuticals
KalVista Pharmaceuticals is dedicated to developing transformative oral treatments for rare diseases that currently lack effective therapies. The company is well-known for its groundbreaking product, EKTERLY®, which is recognized as the first and only oral on-demand treatment for hereditary angioedema (HAE). The team at KalVista continues its commitment to collaborating with the global HAE community to enhance both treatment options and patient care worldwide. For further information regarding KalVista Pharmaceuticals, interested parties can visit their official website or follow them on various social media platforms including LinkedIn, X, Facebook, and Instagram.
For media inquiries, Ryan Baker, Head of Investor Relations, and Molly Cameron, Director of Corporate Communications, are available for contact, further emphasizing the company’s openness and commitment to stakeholder engagement.
This latest development illustrates KalVista Pharmaceuticals’ proactive approach in securing a skilled workforce, which is crucial in their ongoing mission to address significant unmet medical needs.
Related
